CA1139671A - Analgesic mixture of nalbuphine and acetaminophen - Google Patents
Analgesic mixture of nalbuphine and acetaminophenInfo
- Publication number
- CA1139671A CA1139671A CA000352011A CA352011A CA1139671A CA 1139671 A CA1139671 A CA 1139671A CA 000352011 A CA000352011 A CA 000352011A CA 352011 A CA352011 A CA 352011A CA 1139671 A CA1139671 A CA 1139671A
- Authority
- CA
- Canada
- Prior art keywords
- nalbuphine
- acetaminophen
- composition
- analgesic
- hcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 39
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 title claims abstract description 38
- 229960000805 nalbuphine Drugs 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 230000000202 analgesic effect Effects 0.000 title abstract description 20
- 239000003937 drug carrier Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229920000881 Modified starch Polymers 0.000 description 7
- 239000004368 Modified starch Substances 0.000 description 7
- 235000019426 modified starch Nutrition 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- -1 phenyl- Chemical group 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- FYYHWMGAXLPEAU-OUBTZVSYSA-N magnesium-25 atom Chemical compound [25Mg] FYYHWMGAXLPEAU-OUBTZVSYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US040,281 | 1979-05-18 | ||
| US06/040,281 US4237140A (en) | 1979-05-18 | 1979-05-18 | Analgesic mixture of nalbuphine and acetaminophen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1139671A true CA1139671A (en) | 1983-01-18 |
Family
ID=21910135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000352011A Expired CA1139671A (en) | 1979-05-18 | 1980-05-15 | Analgesic mixture of nalbuphine and acetaminophen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4237140A (Direct) |
| EP (1) | EP0019282B1 (Direct) |
| JP (1) | JPS55154917A (Direct) |
| AU (1) | AU529764B2 (Direct) |
| CA (1) | CA1139671A (Direct) |
| DE (1) | DE3061597D1 (Direct) |
| HU (1) | HU178867B (Direct) |
| IE (1) | IE49988B1 (Direct) |
| IL (1) | IL60095A (Direct) |
| NZ (1) | NZ193695A (Direct) |
| PH (1) | PH15265A (Direct) |
| ZA (1) | ZA802916B (Direct) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4322427A (en) * | 1981-04-16 | 1982-03-30 | Bristol-Myers Company | Analgetic compositions and methods of use |
| US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
| US4407804A (en) * | 1982-06-30 | 1983-10-04 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and indomethacin |
| US4404211A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and flurbiprofen |
| US4407805A (en) * | 1982-06-30 | 1983-10-04 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and zomepirac |
| US4404208A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and tiflamizole |
| US4404209A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and sulindac |
| US4404210A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and ibuprofen |
| US4402962A (en) * | 1982-06-30 | 1983-09-06 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole |
| AU565634B2 (en) * | 1982-06-30 | 1987-09-24 | E.I. Du Pont De Nemours And Company | Synergistic compositions of nalbuphine and non-narcotic analgesic compounds |
| US4777174A (en) * | 1982-07-22 | 1988-10-11 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
| GB2134786B (en) * | 1982-07-22 | 1986-05-08 | Richardson Vicks Inc | Improved analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
| US4656177A (en) * | 1982-07-22 | 1987-04-07 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
| US4600579A (en) * | 1983-06-07 | 1986-07-15 | Mallinckrodt, Inc. | N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same |
| US4722928A (en) * | 1985-12-02 | 1988-02-02 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes |
| RU2121346C1 (ru) | 1991-09-06 | 1998-11-10 | МакНейлэб, Инк. | Композиция, включающая вещество трамадол и ацетаминофен, и способ лечения с ее использованием |
| US5558876A (en) * | 1995-03-29 | 1996-09-24 | Alcon Laboratories, Inc. | Topical ophthalmic acidic drug formulations |
| US6348216B1 (en) * | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
| US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| WO1999032119A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
| KR20020071032A (ko) | 2000-02-08 | 2002-09-11 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 효능제와 길항제를 함유하는 서방성 조성물 |
| ES2361148T3 (es) | 2001-05-11 | 2011-06-14 | Endo Pharmaceuticals Inc. | Forma de dosificación de opioides de liberación controlada resistente al abuso. |
| SI1416842T1 (sl) | 2001-07-18 | 2009-06-30 | Euro Celtique Sa | Farmacevtske kombinacije oksikodona in naloksona |
| CA2457361C (en) | 2001-08-06 | 2008-11-04 | Christopher Breder | Opioid agonist formulations with releasable and sequestered antagonist |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
| DE20321531U1 (de) | 2002-04-05 | 2007-11-22 | Euro-Celtique S.A. | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfaßt |
| AU2003270778B2 (en) | 2002-09-20 | 2009-10-08 | Alpharma Pharmaceuticals, Llc | Sequestering subunit and related compositions and methods |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| EP1931315B1 (en) * | 2005-08-24 | 2013-10-16 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| US8394812B2 (en) | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| KR20150029762A (ko) | 2006-06-19 | 2015-03-18 | 알파마 파머슈티컬스 엘엘씨 | 약제학적 조성물 |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| UY32487A (es) | 2009-03-10 | 2010-06-30 | Euro Celtique Sa | Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona |
| WO2015011189A1 (en) | 2013-07-23 | 2015-01-29 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| HRP20220978T1 (hr) | 2013-12-24 | 2022-11-11 | Virginia Commonwealth University | Upotreba oksidiranih kolesterol sulfata (ocs) za liječenje disfunkcije bubrega |
| JOP20190094A1 (ar) * | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| US11260048B2 (en) | 2017-10-03 | 2022-03-01 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
| CN113164469A (zh) * | 2018-09-03 | 2021-07-23 | 雅各生技有限公司 | 双那布扶林己二酸酯和乙酰胺酚的药物制剂及治疗疼痛的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL26896A (en) * | 1966-01-19 | 1970-11-30 | Endo Lab | 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones |
| US4029798A (en) * | 1975-06-02 | 1977-06-14 | Sumitomo Chemical Company, Limited | Analgetic composition |
| JPS5946205B2 (ja) * | 1976-01-01 | 1984-11-10 | 科研製薬株式会社 | ベンゾイル誘導体を有効成分とする消炎鎮痛剤 |
-
1979
- 1979-05-18 US US06/040,281 patent/US4237140A/en not_active Expired - Lifetime
-
1980
- 1980-05-13 NZ NZ193695A patent/NZ193695A/en unknown
- 1980-05-13 AU AU58351/80A patent/AU529764B2/en not_active Ceased
- 1980-05-15 DE DE8080102696T patent/DE3061597D1/de not_active Expired
- 1980-05-15 EP EP80102696A patent/EP0019282B1/en not_active Expired
- 1980-05-15 CA CA000352011A patent/CA1139671A/en not_active Expired
- 1980-05-16 ZA ZA00802916A patent/ZA802916B/xx unknown
- 1980-05-16 PH PH24035A patent/PH15265A/en unknown
- 1980-05-16 HU HU80801223A patent/HU178867B/hu not_active IP Right Cessation
- 1980-05-16 IL IL60095A patent/IL60095A/xx unknown
- 1980-05-16 IE IE1019/80A patent/IE49988B1/en not_active IP Right Cessation
- 1980-05-17 JP JP6469980A patent/JPS55154917A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE3061597D1 (en) | 1983-02-17 |
| IE801019L (en) | 1980-11-18 |
| AU5835180A (en) | 1980-11-20 |
| IE49988B1 (en) | 1986-01-22 |
| JPH0144684B2 (Direct) | 1989-09-29 |
| HU178867B (en) | 1982-07-28 |
| EP0019282B1 (en) | 1983-01-12 |
| JPS55154917A (en) | 1980-12-02 |
| PH15265A (en) | 1982-11-02 |
| AU529764B2 (en) | 1983-06-16 |
| IL60095A (en) | 1982-12-31 |
| NZ193695A (en) | 1984-05-31 |
| ZA802916B (en) | 1981-12-30 |
| US4237140A (en) | 1980-12-02 |
| EP0019282A1 (en) | 1980-11-26 |
| IL60095A0 (en) | 1980-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1139671A (en) | Analgesic mixture of nalbuphine and acetaminophen | |
| EP0566709B1 (en) | Composition comprising a tramadol compound and acetaminophen, and its use | |
| CA2077637C (en) | Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use | |
| US5516803A (en) | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug | |
| CA1200501A (en) | Nalbuphine - narcotic analgesic composition and method of producing analgesia | |
| NO302736B1 (no) | Farmasöytisk preparat omfattende tramadol og ibuprofen | |
| US4322427A (en) | Analgetic compositions and methods of use | |
| US4282215A (en) | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | |
| US4260629A (en) | Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid | |
| US3865933A (en) | Analgesic composition | |
| CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
| US8148425B2 (en) | Pharmaceutical composition containing phloroglucinol and paracetamol | |
| CA2076149A1 (en) | Potentiation of antitussive effect of dextromethorphan | |
| CN101778632B (zh) | 综合失调症的治疗或预防药 | |
| US4404209A (en) | Analgesic mixture of nalbuphine and sulindac | |
| EP0024690B1 (en) | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | |
| CA1200499A (en) | Synergistic compositions of nalbuphine and non- narcotic analgesic compounds | |
| US3784702A (en) | Anti-tussive compositions | |
| JPS646169B2 (Direct) | ||
| WO1997048390A1 (en) | Analgesics combining acetaminophen with meclizine | |
| WO1998058637A1 (en) | Acetaminophen and diphenhydramine analgesics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |